Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Trends and Opportunities 2025-2034: A Comprehensive Guide to Growth Insights
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What Factors Are Driving the Anticipated Growth Rate of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Through 2034?
The market for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) has seen explosive growth in recent times. The market will expand from a value of $10.36 billion in 2024 to a projected $13.32 billion in 2025, representing a compound annual growth rate (CAGR) of 28.5%. The substantial growth during the previous period can be attributed to a rising incidence of ATTR-CM, an increased prevalence of transthyretin amyloidosis in the elderly population, growing awareness among both healthcare professionals and patients, and enhancements in healthcare services consciousness and quality.
In the coming years, the market size of transthyretin amyloid cardiomyopathy (ATTR-CM) treatment is anticipated to witness enormous growth. It is projected to reach $35.93 billion by 2029, growing at a compound annual growth rate (CAGR) of 28.2%. The market growth during the forecast period can be credited to the escalating prevalence of transthyretin amyloidosis, increasing diagnoses of neuropathic conditions, a surge in the older population, and higher demand for specific drugs to treat the symptoms of this rare disorder, alongside the growing need for healthcare. Key trends for the forecast period will be innovative diagnostic tools, cutting-edge strategies for therapy management, new and targeted treatments for transthyretin amyloidosis, and advanced diagnostic methods, including cardiac MRI techniques.
Which Primary Drivers Are Supporting the Continued Expansion of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
The growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is anticipated to be driven by the increasing presence of chronic diseases, which are long-lasting disorders that develop gradually and last more than a year, often necessitating regular medical care. Factors such as aging populations, inactive lifestyles, unhealthy eating habits, escalating obesity, and exposure to environmental pollutants contribute to the growing prevalence of these diseases. ATTR-CM treatment aids by stabilizing transthyretin, reducing amyloid accumulation, enhancing heart functionality, and easing symptoms to efficiently control associated chronic ailments. For example, in September 2023, the World Health Organization, a Swiss-based United Nations affiliate, reported that of 41 million deaths, 74% were caused by non-communicable diseases (NCDs) or chronic diseases per annum. Globally, there were 17.9 million deaths due to cardiovascular diseases, 9.3 million due to cancer, 4.1 million due to chronic respiratory conditions, and 2.0 million due to diabetes. Hence, the escalating prevalence of chronic diseases is propelling the ATTR-CM treatment market.
Get Your Free Sample of the Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp
Who are the major industry leaders accelerating growth in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment market?
Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG
Which Current Trends Are Having the Most Impact on the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
Leading corporations in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment industry are concentrating on the creation of novel remedies for ATTR-CM, such as oral prescription drugs designed to control and stabilize transthyretin (TTR) proteins or to minimize the buildup of amyloid fibrils in cardiac tissue. Such oral prescription medicines are usually administered in tablet, capsule, or liquid form, prescribed by a healthcare practitioner. To illustrate, BridgeBio Pharma Inc., a bio-tech firm based in the United States, was granted approval for Attruby (acoramidis) by the U.S. Food and Drug Administration in November 2024. This drug stabilizes the TTR protein, which in turn reduces heart-related mortalities and hospital admissions. Clinical studies suggest that it is generally well-tolerated and provides immediate benefits by delving into the underlying causes of the disease.
Get Instant Access to the Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Report with Swift Delivery!
What Are the Major Categories and Their Growth Dynamics in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market covered in this report is segmented –
1) By Type: Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Other Types
2) By Indication: Wild type ATTR Amyloidosis, Hereditary ATTR amyloidosis
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Transthyretin Stabilizers: Tafamidis, Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin, Ibuprofen, Other NSAIDs
3) By RNAi Therapy: Patisiran, Vutrisiran
4) By Other Types: Gene Silencing Therapies, Immunotherapy Approaches, Emerging Small Molecule Therapies
Which Regions Are Key Players in the Growth of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Elements Shape the Definition of the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment refers to medical therapies and interventions aimed at managing ATTR-CM, a progressive and life-threatening disease caused by the buildup of misfolded transthyretin (TTR) proteins in the heart, leading to restrictive cardiomyopathy and heart failure.
Browse Through More Similar Reports By The Business Research Company:
Hepatitis Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hepatitis-drugs-global-market-report
Non-Alcoholic Steatohepatitis Treatment Global Market Report 2025
Hepatitis Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
